Trials / Completed
CompletedNCT02702986
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)
Immunostimulating Interstitial Laser Thermotherapy in Patients With Locally Advanced Pancreatic Cancer: Results of a Prospective, Open, Non Comparative Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Universita di Verona · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | immunostimulating Interstitial Laser Thermotherapy | Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer. |
| DEVICE | Laser |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2021-10-01
- Completion
- 2021-10-01
- First posted
- 2016-03-09
- Last updated
- 2022-04-21
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02702986. Inclusion in this directory is not an endorsement.